



**OKLAHOMA STATE BUREAU OF NARCOTICS
AND DANGEROUS DRUGS CONTROL**

419 N.E. 38th Terrace
Oklahoma City, Oklahoma 73105
TELEPHONE 405-521-2885 · 1-800-522-8031

May 8, 2026

To: OBNDD Marijuana Business Registrants

Re: OBNDD Director's Guidance Regarding the United States Department of Justice (USDOJ) Final Order concerning scheduling of Marijuana and the OBNDD registration requirements¹

On April 28, 2026, the U.S. Department of Justice issued AG Order No. 6754-2026 (hereinafter "Final Order") rescheduling some marijuana to Schedule III of the Controlled Substances Act (CSA). This letter is being sent to inform you about the impact that this has on your responsibilities as an OBNDD registrant.

OBNDD Medical Marijuana Manufacturers and Distributors are Required to Provide Proof of Possessing a Schedule III Registration From the DEA

Pursuant to the Final Order, marijuana in any form covered by a state medical marijuana license was placed in Schedule III of the CSA. Therefore, a manufacturer or distributor participating in a state's medical marijuana program is required to obtain a registration from the United States Drug Enforcement Administration (DEA). Consistent with 63 O.S. §2-101 et. seq. and Title 475 of the Oklahoma Administrative Code, every registrant who is a distributor or manufacturer of medical marijuana products must comply with federal law and, as such, shall be required to obtain a DEA registration. Failure to obtain a DEA registration could result in OBNDD administrative sanctions up to and including the potential revocation of an registrant's OBNDD registration(s). This is consistent with the requirements in place for other Schedule III registrants currently regulated by OBNDD.

¹ It should be noted that this guidance only applies to OBNDD administrative requirements. This is not intended to take a position as to potential administrative requirements of any other agency, state or federal. Furthermore, this guidance also does not apply to potential criminal penalties, either state or federal, for engaging in the manufacturing or distribution of marijuana.

Information Concerning Potential OBNDD Administrative Action Related to the Manufacturing or Distribution of Marijuana without the Proper DEA Registration.

According to the Final Order, any state licensed medical marijuana manufacturer or distributor who has applied to DEA for the appropriate DEA registration within sixty days of the Final Order's publication in the Federal Register may engage in the manufacture, distribution and/or dispensing of medical marijuana products during the pendency of its DEA application. The DEA administrator is required to make every effort to process those applications received during this sixty-day period within six months.

To ensure compliance with these federal regulations and minimize any impact on lawfully operating entities, OBNDD will not consider pursuing administrative action on medical marijuana businesses registered with OBNDD for the manufacturing or distribution of marijuana without the required DEA registration until January 1, 2027. It is strongly recommended that all OBNDD registrants authorized to manufacture or distribute medical marijuana apply for the appropriate DEA registration within the sixty-day period after the April 28, 2026, publication of the Final Order. By timely submitting an application to the DEA, a registrant will not be subjected to OBNDD administrative action for the manufacturing, or distribution of marijuana without a DEA registration while the DEA application filed within the sixty-day period remains pending. Failure to timely submit an application to the DEA would render any manufacturing or distribution of medical marijuana products without a DEA registration to be in violation of the Final Order. These activities could subject a registrant to OBNDD administrative sanctions up to and including the potential revocation of an registrant's OBNDD registration(s).

Questions Concerning Compliance

OBNDD cannot provide legal advice concerning compliance with federal law or Oklahoma statutes. Furthermore, nothing included in this letter is intended to be taken as legal advice concerning the obligations of a registrant set forth in either federal law or Oklahoma statutes. This letter is merely being provided to inform medical marijuana businesses of their administrative responsibilities. If there are additional questions concerning compliance with either federal, state, or administrative law, a registrant should consult with an attorney.

Respectfully,



Donnie Anderson
Director
Oklahoma Bureau of Narcotics
and Dangerous Drugs Control